Home / Innere Medizin / Onkologie / ESMO 2018: Die vier wichtigsten Studien zu frühem Mammakarzinom

OA Dr. Christoph Suppan

ESMO 2018: Die vier wichtigsten Studien zu frühem Mammakarzinom

OA Dr. Christoph Suppan, Universitätsklinik für Innere Medizin, Graz, fasst die neuen Daten bei frühem Brustkrebs zusammen und erklärt, wie Onkologen zu einer höheren Therapieadhärenz beitragen können.

Interviewpartner:

Redaktion:

Produktion:

Abstracts

LBA14_PR - The HOBOE-2 multicenter randomized phase 3 trial in premenopausal patients with hormone-receptor positive early breast cancer
comparing Triptorelin plus either Tamoxifen or Letrozole or Letrozole + Zoledronic acid.
F. Perrone

185O_PR - Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO
cohort
B. Pistilli

186O - Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial
M.V. Dieci

LBA12_PR - PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results
C. Hulme

Quelle: ESMO 2018

LOGIN

Login

Passwort vergessen?